{"nctId":"NCT03066804","briefTitle":"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients","startDateStruct":{"date":"2017-08-22","type":"ACTUAL"},"conditions":["Heart Failure With Preserved Ejection Fraction"],"count":2572,"armGroups":[{"label":"sacubitril/valsartan (LCZ696)","type":"EXPERIMENTAL","interventionNames":["Drug: sacubitril/valsartan","Drug: Placebo to match enalapril","Drug: Placebo to match valsartan"]},{"label":"Comparator","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril","Drug: Valsartan","Drug: Placebo to match sacubitril/valsartan"]}],"interventions":[{"name":"sacubitril/valsartan","otherNames":[]},{"name":"Enalapril","otherNames":[]},{"name":"Valsartan","otherNames":[]},{"name":"Placebo to match sacubitril/valsartan","otherNames":[]},{"name":"Placebo to match enalapril","otherNames":[]},{"name":"Placebo to match valsartan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Left ventricular ejection fraction (LVEF) \\>40% by echo within 6 months prior to study entry or during the screening epoch\n* Symptom(s) of heart failure (HF) requiring treatment with diuretics (including loop, or thiazide diuretics, or mineralocorticoid antagonist \\[MRAs\\]) for at least 30 days prior to study entry\n* NYHA class II-IV\n* Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram.\n* NT-proBNP \\> 220 pg/mL for patients with no atrial fibrillation/atrial flutter (AF) or \\>600 pg/mL for patients with AF\n* KCCQ clinical summary score \\< 75\n* Patients on ACEi or ARB therapy must have a history of HTN\n\nExclusion Criteria:\n\n* Any prior measurement of LVEF ≤ 40%, under stable conditions\n* Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months , or urgent percutaneous coronary intervention (PCI) within 3 months or an elective PCI within 30 days prior to study entry\n* Any clinical event within the 6 months prior to Visit 1 that could have reduced the LVEF (eg MI, coronary artery bypass graft \\[CABG\\]), unless an echo measurement was performed after the event confirming the LVEF to be \\>40%\n* Current (within 30 days from Visit 1) acute decompensated HF requiring therapy.\n* Current (within 30 days from Visit 1) use of renin inhibitor(s), dual RAS blockade or LCZ696\n* History of hypersensitivity to LCZ696 or its components\n* Patients with a known history of angioedema\n* Walk distance primarily limited by non-cardiac comorbid conditions at study entry\n* Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) \\<10 g/dL males and \\< 9.5 g/dL females, or body mass index (BMI) \\> 40 kg/m\\^2.\n* Systolic blood pressure (SBP) ≥ 180 mmHg at study entry, or SBP \\>150 mmHg and \\<180 mmHg at study entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP \\< 110 mmHg at study entry.\n* Patients with HbA1c \\> 7.5% not treated for diabetes\n* Patients with prior major organ transplant or intent to transplant (ie on transplant list)\n* eGFR \\< 30 ml/min/1.73 m\\^2 as measured by MDRD at screening\n* Serum potassium \\> 5.2 mmol /L (or equivalent plasma potassium value) at study entry\n* History or presence of any other disease with a life expectancy of \\< 3 years\n* Pregnant or nursing women or women of child-bearing potential unless they are using highly effective methods of contraception\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12","description":"To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8218","spread":null},{"groupId":"OG001","value":"0.9828","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24","description":"Change from baseline in 6-minute walk distance (6MWD) will be reported at Week 24. The 6 MWT will be performed in accordance with the guidelines of the American Thoracic Society 2002.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6935","spread":null},{"groupId":"OG001","value":"12.1920","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24","description":"The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3399","spread":null},{"groupId":"OG001","value":"11.8168","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24","description":"Percentage of patients with KCCQ CSS deterioration ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.49","spread":null},{"groupId":"OG001","value":"16.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24","description":"Percentage of patients with KCCQ CSS improvement ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.94","spread":null},{"groupId":"OG001","value":"65.70","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in NYHA Functional Class at Week 24","description":"NYHA classification is a subjective physician's assessment of patient's functional capacity and symptomatic status and can change frequently over time.\n\nClass I - No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF Class II - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF Class III - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF Class IV - Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest\n\nThe NYHA class change will be analyzed as a three category ordinal variable with levels: \"improved\", \"unchanged\", and \"worsened\", defined by at least one class improvement, no change, at least one class worsening, in NYHA class, respectively.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.62","spread":null},{"groupId":"OG001","value":"24.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.23","spread":null},{"groupId":"OG001","value":"71.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":null},{"groupId":"OG001","value":"4.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24","description":"The SF-36 PCS score reflects the measure of quality of life based on the 36 questions which evaluate the person's physical, emotional, and mental status, including general health. Specifically, the SF-36 PCS score focuses on assessing the person's physical status. The score ranges from 0 to 100 with a higher score indicating a better status of physical wellbeing (range = 0 \"worst\"-100 \"best\").","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5405","spread":null},{"groupId":"OG001","value":"2.6975","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":186,"n":1280},"commonTop":["Glomerular filtration rate decreased","Hyperkalaemia","Renal impairment","Urine albumin/creatinine ratio increased","Haematuria"]}}}